Table 1.
Patient demographics and clinical data. NA denotes samplesunavailable for analysis.
| Patient | Age (years) |
Sex | No.of reovirus infusions |
Time between final reovirus infusion and surgery (days) |
ras mutation status |
Toxicity (grade) |
|---|---|---|---|---|---|---|
| 1 | 74 | M | 3 | 7 | 12ASP | Nausea (2) |
| Constipation (2) | ||||||
| Headache (2) | ||||||
| Pyrexia (2) | ||||||
| Myalgia (2) | ||||||
| 2 | 62 | M | 5 | 11 | 13ASP, 12VAL |
None |
| 3 | 73 | M | 5 | 21 | 12VAL | None |
| 4 | 66 | M | 5 | 19 | 12ASP | Pyrexia (2) |
| 5 | 62 | M | 5 | 14 | 12CYS | Rigors (2) |
| 6 | 50 | F | 5 | 6 | None | Myalgia (1) |
| Pyrexia (1) | ||||||
| 7 | 58 | M | 4 | 28 | None | Pyrexia (1) |
| Leukopenia (2) | ||||||
| 8 | 65 | F | 1 | 10 | NA | Insomnia (2) |
| Hallucination (1) | ||||||
| Myalgia (2) | ||||||
| Rigors (2) | ||||||
| 9 | 70 | M | 5 | 6 | None | Pyrexia (1) |
| 10 | 63 | M | 5 | 14 | None | Pyrexia (1) |
| Hypotension (1) |